Study of pembrolizumab and lenvatinib for high-risk cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests whether adding two drugs—pembrolizumab (an immunotherapy) and lenvatinib (a targeted therapy)—to the standard chemoradiation and brachytherapy can improve outcomes for women with high-risk locally advanced cervical cancer. The goal is to see if this combination helps control the cancer better than usual treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of cervical cancer called squamous cell carcinoma at stage III, or adenocarcinoma at stage IB to II, as defined by your doctor.
- You have been scheduled to receive chemoradiation (chemo plus radiation) and a special type of radiation called brachytherapy, with the goal of finishing within 50 days.
- Your kidney, liver, and blood counts are at an acceptable level, and your blood pressure is controlled (below 150/90).
- You have not had major surgery within 3 weeks before starting the study, and you do not have certain infections (like HIV or active hepatitis B or C) or heart problems that would make the study unsafe.
- You are able to provide written consent to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies whether pembrolizumab and lenvatinib can improve outcomes in people with advanced cervical cancer that has grown or stopped responding to earlier treatments. It may help by boosting the immune system and slowing cancer growth.
This trial tests if giving the immunotherapy drug pembrolizumab before and after standard chemoradiation works better than the standard approach for people with high-risk cervical cancer that has spread locally.
This study tests a combination of two drugs, pembrolizumab (an immunotherapy) and lenvatinib (a targeted therapy), for people with cervical cancer that has come back or spread. The goal is to see if this drug combination can shrink tumors or slow the cancer's growth.
This trial tests a combination of new immunotherapy drugs (LB1410 and maybe LB4330) with lenvatinib (a targeted therapy) in patients with advanced cervical cancer that came back or spread. The goal is to see if this combo shrinks tumors or slows the cancer better than standard options.
This trial tests adding an immunotherapy drug (serplulimab) to standard chemoradiation after cervical cancer surgery. It is for patients with at least two high-risk features, like lymph node spread or deep invasion, to see if it helps prevent the cancer from coming back.
This study tests whether adding a new immunotherapy drug, envafolimab, to standard chemotherapy and radiation can improve outcomes for patients with locally advanced cervical cancer. You may receive the experimental drug along with your usual treatment, which could help your body fight the cancer more effectively.
Hear when a new Cervical Cancer by FIGO Stage 2018 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.